In a filing, Halozyme Therapeutics Inc revealed its Director Henderson Jeffrey William unloaded Company’s shares for reported $0.29 million on Mar 03 ’25. In the deal valued at $58.69 per share,5,000 shares were sold. As a result of this transaction, Henderson Jeffrey William now holds 33,611 shares worth roughly $2.15 million.
Then, LaBarre Michael J. sold 10,000 shares, generating $581,244 in total proceeds. Upon selling the shares at $58.12, the SVP, CHIEF TECHNICAL OFFICER now owns 175,453 shares.
Before that, LaBarre Michael J. sold 10,000 shares. Halozyme Therapeutics Inc shares valued at $580,534 were divested by the SVP, CHIEF TECHNICAL OFFICER at a price of $58.05 per share. As a result of the transaction, LaBarre Michael J. now holds 185,453 shares, worth roughly $11.87 million.
Wells Fargo downgraded its Halozyme Therapeutics Inc [HALO] rating to an Equal weight from a an Overweight in a research note published on October 07, 2024; the price target was increased to $62 from $58. A number of analysts have revised their coverage, including JP Morgan’s analysts, who decreased its forecast for the stock in mid September from “an Overweight” to “a Neutral”. Piper Sandler also remained covering HALO and has decreased its forecast on June 07, 2024 with a “Neutral” recommendation from previously “an Overweight” rating. TD Cowen started covering the stock on February 29, 2024. It rated HALO as “an Outperform”.
Price Performance Review of HALO
On Monday, Halozyme Therapeutics Inc [NASDAQ:HALO] saw its stock fall -1.75% to $64.02. Over the last five days, the stock has gained 1.70%. Halozyme Therapeutics Inc shares have risen nearly 33.91% since the year began. Nevertheless, the stocks have risen 58.54% over the past one year. While a 52-week high of $65.53 was reached on 03/24/25, a 52-week low of $37.73 was recorded on 01/03/25. SMA at 50 days reached $58.27, while 200 days put it at $54.88.
Levels Of Support And Resistance For HALO Stock
The 24-hour chart illustrates a support level at 62.58, which if violated will result in even more drops to 61.14. On the upside, there is a resistance level at 65.73. A further resistance level may holdings at 67.44. The Relative Strength Index (RSI) on the 14-day chart is 69.34, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 2.28, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 25.48%. Stochastics %K at 88.73% indicates the stock is a selling.
How much short interest is there in Halozyme Therapeutics Inc?
A steep rise in short interest was recorded in Halozyme Therapeutics Inc stocks on 2025-02-28, growing by 0.69 million shares to a total of 9.75 million shares. Yahoo Finance data shows the prior-month short interest on 2025-01-31 was 9.06 million shares. There was a rise of 7.1%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on July 24, 2023 when H.C. Wainwright began covering the stock and recommended ‘”a Buy”‘ rating along with a $61 price target.
